Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Boothbay Fund Management LLC

Boothbay Fund Management LLC lessened its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 75.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,534 shares of the biopharmaceutical company's stock after selling 32,384 shares during the period. Boothbay Fund Management LLC owned about 0.09% of Corbus Pharmaceuticals worth $124,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in shares of Corbus Pharmaceuticals by 27.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock worth $114,000 after purchasing an additional 1,172 shares during the period. Geode Capital Management LLC boosted its stake in Corbus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company's stock valued at $5,154,000 after buying an additional 18,702 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Corbus Pharmaceuticals by 4.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company's stock worth $1,155,000 after purchasing an additional 4,239 shares during the last quarter. Altium Capital Management LLC raised its position in shares of Corbus Pharmaceuticals by 97.4% during the 4th quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company's stock valued at $4,543,000 after buying an additional 190,000 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Corbus Pharmaceuticals by 769.4% during the 4th quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company's stock valued at $1,641,000 after purchasing an additional 123,100 shares during the last quarter. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Stock Performance

NASDAQ:CRBP traded down $0.18 during trading hours on Friday, hitting $6.47. The company's stock had a trading volume of 64,562 shares, compared to its average volume of 360,243. The business's 50-day moving average is $6.33 and its two-hundred day moving average is $10.93. The company has a market capitalization of $79.14 million, a PE ratio of -1.38 and a beta of 3.19. Corbus Pharmaceuticals Holdings, Inc. has a 52-week low of $4.64 and a 52-week high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13). As a group, analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CRBP shares. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a report on Thursday, March 6th. B. Riley reaffirmed a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday. Wedbush reissued an "outperform" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. Oppenheimer decreased their price target on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a report on Wednesday. Finally, HC Wainwright cut their price target on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $50.88.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.